About Apogenix
Company Profile
Apogenix is a biopharmaceutical company developing innovative protein therapeutics, targeting both blockbuster indications and niche markets. The lead product, APG101, entered a controlled Phase II proof-of-concept study with glioblastoma patients in December 2009. Apogenix’s IL-4-blockers, currently at preclinical stage, will be developed for the treatment of solid tumours.
Events
We will attend the following conferences and would appreciate the opportunity to meet up for a discussion about partnering.
Strategy
Apogenix will develop novel drug candidates no later than upon completion of the Phase II proof-of-concept studies in man before out-licensing to commercial partners.
Investors
Since its inception in 2005 the company has raised
€ 48 750 000. Apogenix’ main investor is the Dietmar Hopp family.
Contact
Apogenix GmbH
Im Neuenheimer Feld 584, 69120 Heidelberg, Germany
Phonework: +49 (0) 6221 58608 0
